These consisted of markers of astrocytic and microglial activation (GFAP, vimentin, galectin-1, and clusterin) and indicators of neurodegenerative disease (ApoE and serpinA3N) that each demonstrated significant prion effects and PAM effects from the MS proteomic analysis (Fig. 5A). The gene discussed is CLU; the disease is neurodegenerative disease.